SummaryRMgm-5574
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging |
Reference (PubMed-PMID number) | Not published (yet) |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA cl15cy1 |
Other information parent line | A reference wild type clone from the ANKA strain of P. berghei (PubMed: PMID: 17406255). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Hernandez S, Franke-Fayard B, Janse CJ, Bushell ESC |
Name Group/Department | The Laboratory for Molecular Infection Medicine Sweden (MIMS) |
Name Institute | Umeå University |
City | Umeå |
Country | Sweden |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5574 |
Principal name | PbEMAP3-myc |
Alternative name | PbEMAP3::3xcMYC |
Standardized name | exp. 3084 |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | In schizonts EMAP3-myc shows a location largely concentrated to the iRBC membrane. EMAP3 is expressed already in ring forms, where it appears closely associated with the nucleus. Already in early trophozoites EMAP3-myc is found at the iRBC membrane and EMAP3 remains located at the iRBC membrane in schizonts. |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Published in: bioRxiv preprint doi: https://doi.org/10.1101/2024.05.28.596273 Additional information How EMAP3 is is oriented on the iRBC membrane was identified through surface shaving using trypsin and permeabilisation with Triton X-100. EMAP3-myc is detectable without prior permeabilisation, demonstrating that the C-terminal end of the protein containing the myc tag is exposed on the iRBC surface. This is supported by the observation that the EMAP3-myc signal is lost upon treatment with trypsin. In contrast, EMAP1-myc could only be detected when the cell is permeabilised, indicating that the C-terminus of EMAP1 is not exposed on the surface of the iRBC. Despite its association with the iRBC membrane, EMAP1 lacks predicted transmembrane domains and the orientation of the protein at the iRBC membrane was not further studied. |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0825900 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0925100 | ||||||||||||||||||||||||||
Gene product | conserved Plasmodium protein, unknown function | ||||||||||||||||||||||||||
Gene product: Alternative name | EMAP3, erythrocyte membrane associated protein 3 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | 3x-myc | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | The emap3 ko (PBANKA_0825900) plasmid was generated by amplifying 0,5 kb (5’) and (3’) homology arms flanking the emap3 open reading frame (ORF) from P. berghei genomic DNA and subsequently cloned into the pL0001 plasmid (www.mr4.com) carrying the mutated tgdhfr/ts (Toxoplasma gondii dihydrofolate reductase-thymidylate synthase) selection marker expressed under control of the pbdhfr/ts (P. berghei dihydrofolate reductase-thymidylate synthase) 5’ and 3’ UTRs (untranslated regions). The resulting emap3 ko pL2296 plasmid was linearised (using KpnI, NotI, ScaI) and transfected into the P. berghei mCherry_Luc background line (hsp70p:mCherry eef1ap:Luciferase, 1868Cl1) and cloned by standard limited dilution cloning. The emap3-myc (PBANKA_0825900) tagging vector was generated by amplifying a 0,7 kb 3’ fragment of emap3 that was cloned in-frame with the coding sequence for myc, which upon integration of the vector into the emap3 target locus inserts a 3’(C-terminal) myc tag. To this end the homology arm fragment was amplified from P. berghei genomic DNA and cloned into the pL1672 vector containing the selection marker tgdhfr/ts using BamHI/EcoRI restriction enzymes to generate the emap3-myc vector (pL2302), which was linearised with NdeI prior to transfection. The emap1-myc (PBANKA_0836800, pL1594), emap2-myc (PBANKA_0316800, pL2358) and smac-myc (PBANKA_0100600, pL1435) tagging vectors were generated by replacing the mCherry tag with a 3x-myc tag in existing C-terminal tagging vectors carrying the tgdhfr/ts selection marker. The vectors were linearised prior to transfection using NdeI (pL1594), ClaI (pL2358) or NdeI (pL1435). The resulting 3x-myc tagging vectors were transfected either into PbANKA cl15cy1 reference line, (emap1-myc, line 1583 and emap3-myc, line 3084), mCherry_Luc (emap2-myc, line 3296) or GFP_Luc, (smac-myc, line 1413). | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |